These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 23106270)

  • 61. New generation methods for drug susceptibility testing for tuberculosis.
    Katoch VM
    Indian J Tuberc; 2008 Apr; 55(2):61-3. PubMed ID: 18516820
    [No Abstract]   [Full Text] [Related]  

  • 62. [Advantages and disadvantages of longer and shorter chemotherapy regimens for multi-drug or rifampicin-resistant tuberculosis].
    Li Q; Li L
    Zhonghua Jie He He Hu Xi Za Zhi; 2019 May; 42(5):333-338. PubMed ID: 31137109
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Bedaquiline.
    Goulooze SC; Cohen AF; Rissmann R
    Br J Clin Pharmacol; 2015 Aug; 80(2):182-4. PubMed ID: 25702772
    [No Abstract]   [Full Text] [Related]  

  • 64. Fluoroquinolone-resistant Mycobacterium tuberculosis, Pakistan, 2005-2009.
    Jabeen K; Shakoor S; Chishti S; Ayaz A; Hasan R
    Emerg Infect Dis; 2011 Mar; 17(3):564-6. PubMed ID: 21392465
    [No Abstract]   [Full Text] [Related]  

  • 65. Is Shorter Treatment Regimen for Multidrug-resistant Tuberculosis feasible in Indian Children?
    Shah I
    Indian Pediatr; 2017 Feb; 54(2):160. PubMed ID: 28285296
    [No Abstract]   [Full Text] [Related]  

  • 66. [The problems in the chemotherapy of tuberculosis taking into account new data on its causative organism].
    Egorov AM; Sazykin IuO
    Antibiot Khimioter; 2000; 45(5):3-5. PubMed ID: 10862346
    [No Abstract]   [Full Text] [Related]  

  • 67. Drug-Susceptible and Multidrug-Resistant Mycobacterium tuberculosis in a Single Patient.
    Baffoe-Bonnie A; Houpt ER; Turner L; Dodge D; Heysell SK
    Emerg Infect Dis; 2019 Nov; 25(11):2120-2121. PubMed ID: 31454310
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Prevalence of pyrazinamide resistance across the spectrum of drug resistant phenotypes of Mycobacterium tuberculosis.
    Whitfield MG; Streicher EM; Dolby T; Simpson JA; Sampson SL; Van Helden PD; Van Rie A; Warren RM
    Tuberculosis (Edinb); 2016 Jul; 99():128-130. PubMed ID: 27450014
    [TBL] [Abstract][Full Text] [Related]  

  • 69. [The re-emergence of tuberculosis: the endemia of multiple-antibiotic-resistant strains].
    Rossi G
    Recenti Prog Med; 1996 Oct; 87(10):487-8. PubMed ID: 9026855
    [No Abstract]   [Full Text] [Related]  

  • 70. Drug susceptibility of tuberculosis isolates in Kansas, 1992-1993.
    Kans Med; 1994 Jun; 95(6):147-8. PubMed ID: 7933767
    [No Abstract]   [Full Text] [Related]  

  • 71. [The rate and pattern of drug resistance in Mycobacterium tuberculosis at various sites of the disease].
    Vishnevskiĭ BI; Steklova LN
    Probl Tuberk Bolezn Legk; 2008; (12):5-8. PubMed ID: 19227317
    [TBL] [Abstract][Full Text] [Related]  

  • 72. [The problem of resistance in the treatment of Mycobacterium infections: new experimental results and combinations for the treatment of tuberculosis and leprosy].
    Seydel JK; Schaper KJ
    Pharm Unserer Zeit; 1995 Nov; 24(6):313-23. PubMed ID: 8592712
    [No Abstract]   [Full Text] [Related]  

  • 73. Bedaquiline (Sirturo) for multidrug-resistant tuberculosis.
    Med Lett Drugs Ther; 2013 Aug; 55(1423):66-8. PubMed ID: 23959388
    [No Abstract]   [Full Text] [Related]  

  • 74. The "source" of drug-resistant TB outbreaks.
    van Helden PD; Victor T; Warren RM
    Science; 2006 Oct; 314(5798):419-20. PubMed ID: 17053131
    [No Abstract]   [Full Text] [Related]  

  • 75. Dynamics of multidrug resistant tuberculosis in Veracruz, México between 2002 and 2008.
    Zenteno-Cuevas R; Rubi A; Fuentes-Dominguez J; Lara-Gonzalez JL; Escobar-Mesa A
    J Infect Dev Ctries; 2010 Nov; 4(11):776-8. PubMed ID: 21252458
    [No Abstract]   [Full Text] [Related]  

  • 76. [Brief discussion on grouping of antituberculosis drugs for treating multidrug- and rifampicin-resistant tuberculosis 2018 update].
    Yao L; Tang SJ
    Zhonghua Jie He He Hu Xi Za Zhi; 2019 May; 42(5):329-332. PubMed ID: 31137108
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Drug-resistant tuberculosis transmission and resistance amplification within families.
    Seddon JA; Warren RM; Enarson DA; Beyers N; Schaaf HS
    Emerg Infect Dis; 2012 Aug; 18(8):1342-5. PubMed ID: 22840848
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Multidrug-resistant Mycobacterium tuberculosis: molecular perspectives.
    Rattan A; Kalia A; Ahmad N
    Emerg Infect Dis; 1998; 4(2):195-209. PubMed ID: 9621190
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Reappraising the use of β-lactams to treat tuberculosis.
    Kurz SG; Bonomo RA
    Expert Rev Anti Infect Ther; 2012 Sep; 10(9):999-1006. PubMed ID: 23106275
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Management of drug-resistant tuberculosis.
    Lange C; Dheda K; Chesov D; Mandalakas AM; Udwadia Z; Horsburgh CR
    Lancet; 2019 Sep; 394(10202):953-966. PubMed ID: 31526739
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.